Peptide PilotPeptide Pilot

Vial duration

Tirzepatide vial duration calculator

Estimate how many weeks one 10 mg Tirzepatide vial covers at your dose and weekly cadence.

Download Peptide PilotiPhone · Free to download

Total doses

4

Lasts

4.0 weeks

Tirzepatide is a once-a-week injection people use to lose weight and improve blood sugar control. It hits two gut-hormone receptors at once — GLP-1 and GIP — which is why it tends to drive larger appetite and weight changes than single-receptor drugs. In the SURMOUNT-1 trial, participants without diabetes lost roughly 20.9% of body weight over 72 weeks on the highest dose. This page covers reconstitution math and weekly dose logging.

How the Tirzepatide vial duration calculator works

This calculator answers the inventory question: at your current dose and weekly cadence, how many weeks will this Tirzepatide vial last? It is the math you need to plan refills before a vial runs dry mid-protocol — especially with peptides like GLP-1s where shipping windows can run several weeks.

The formula is two divisions. Total doses per vial equals vial mg divided by dose mg, rounded down. Weeks of supply equals total doses divided by doses per week. With a 10 mg vial of Tirzepatide, a 2.5 mg dose, and 1 dose per week, the vial covers 4 doses, or about 4.0 weeks of supply.

The three inputs that move the answer: vial mg (set when you bought the vial), dose mg (set by your protocol step), and doses-per-week (set by the peptide's half-life). Once a vial is reconstituted it also has a stability ceiling — most lyophilized peptides reconstituted in BAC water are typically used within four to six weeks of refrigerated storage, so a vial that mathematically lasts twelve weeks may not last twelve weeks in practice.

Use this calculator before opening a new vial to confirm the dose and cadence you have planned will not strand you halfway through. Use it again whenever you titrate up — a dose increase shortens vial life, sometimes dramatically. The calculator is intentionally conservative: it floors total doses, never assumes partial-dose draws, and never extends weeks beyond what whole doses support.

Tirzepatide cadence and how it changes vial life

Weekly subcutaneous injection is the default. Each draw is small enough that almost everyone uses a U-100 insulin syringe rather than a tuberculin syringe.

Tirzepatide protocols often involve gradual dose escalation over months, starting low and increasing every several weeks to reduce gastrointestinal side effects. Logging that escalation in real time — including the exact date and unit count of each step — is what makes the pattern auditable months later.

Vial-aware tracking is especially helpful for tirzepatide because the same vial can support many doses across a long stretch of weeks. Knowing exactly how many doses remain prevents the awkward case of opening a fresh vial and finding that the previous one still had several usable draws left.

Published research protocols for tirzepatide frequently describe a multi-step dose titration schedule that can span five months or longer. A widely studied pattern involves initiating at a 2.5 mg weekly dose and escalating monthly through subsequent tiers: 5 mg, 7.5 mg, 10 mg, 12.5 mg, and a final tier of 15 mg. For researchers documenting their work, this dose-stepping creates a significant planning challenge. To accurately observe such a protocol, one must schedule six discrete dosage levels over the course of the study, each requiring its own precise volume calculation prior to administration.

Storage and shelf life for Tirzepatide

Lyophilized tirzepatide powder is typically stored refrigerated until reconstitution. The in-use reconstituted vial is generally kept refrigerated and used within several weeks. As with all peptides, writing the reconstitution date directly on the vial avoids the common case of finding an unmarked vial in the refrigerator and not knowing whether it is still in its useful window.

Tracking Tirzepatide vials in a real log

Tracking tirzepatide well means linking every dose log entry to the specific vial it came from, recording escalation dates explicitly, and pairing weekly metrics like weight and hunger ratings with the dose history. The escalation history in particular is hard to reconstruct from memory months later, which is why a structured log is more durable than scattered notes.

The escalating dose schedule directly impacts the process of tracking draw volumes, demanding meticulous record-keeping. Using a consistent vial concentration, such as the 5 mg/mL described previously, the logged volume changes with each titration step. A 2.5 mg dose is logged as 0.5 mL or 50 units, a 5 mg dose as 1.0 mL or 100 units, and a 7.5 mg dose as 1.5 mL, which corresponds to 150 units on a larger syringe. A digital tracking tool is critical to accurately convert each scheduled milligram dose to the correct unit measurement for the logbook, ensuring the documented data precisely reflects the protocol being observed without confusion between the different dose tiers.

Common Tirzepatide vial-planning mistakes

  • Reusing the unit count from a previous vial after switching to a new vial that was reconstituted with a different diluent volume.
  • Skipping the escalation date in the log, then being unable to answer when a dose change actually happened.
  • Mixing up tirzepatide milligrams with semaglutide milligrams — the doses are typically much larger for tirzepatide and the math is not interchangeable.
  • Underestimating doses-per-vial on a high-strength vial because the vial looks small even though it contains many weeks of supply.
  • Letting reconstituted tirzepatide sit at room temperature on travel days when a small cooler bag would have kept it refrigerated.
  • Failing to recalculate the correct unit volume for each new dose during a multi-step titration schedule.
  • Attempting to draw a volume greater than 1 mL, such as 1.5 mL or 3 mL, into a standard 1-mL insulin syringe.
  • Mistaking the GIP-to-GLP-1 binding affinity ratio, a fixed molecular property, for a variable that can be adjusted during reconstitution or administration.

Frequently asked questions about Tirzepatide vial duration

How is tirzepatide reconstituted?
By drawing a measured volume of bacteriostatic water and injecting it slowly into the lyophilized vial through the rubber stopper, then swirling — not shaking — until the powder fully dissolves. Diluent volume choices typically range from 2 to 5 mL depending on vial strength and preferred per-dose unit count.
How many units of tirzepatide are in 2.5 mg?
It depends on the concentration. On a 10 mg vial reconstituted with 2 mL of bacteriostatic water (5 mg per mL), 2.5 mg is exactly 50 units on a U-100 syringe. With 4 mL of diluent (2.5 mg per mL), the same dose is 100 units.
Why is tirzepatide dosed weekly?
Because its half-life is roughly five days, which keeps plasma levels stable on a once-weekly schedule. That long half-life is also why a single missed dose has less effect than missing a dose of a daily peptide.
How long does a 10 mg tirzepatide vial last?
At a 2.5 mg weekly dose, a 10 mg vial supports 4 weeks of supply. The vial duration calculator runs the math for any combination of vial size, dose, and frequency.
Is tirzepatide stronger than semaglutide?
They activate different receptor combinations and are dosed at different milligram ranges, so direct milligram comparisons are misleading. The dual GIP/GLP-1 mechanism is the meaningful difference, not the raw milligram count.
Does tirzepatide need to be refrigerated?
Lyophilized powder is generally stored refrigerated, and the reconstituted vial is kept refrigerated and used within several weeks. A small insulated bag is the typical solution for keeping vials cold during travel.
Why does each new tirzepatide vial need its own log?
Because each vial may be reconstituted with a different diluent volume, producing a different concentration. Linking every dose entry to its specific vial keeps the unit count on the syringe accurate to that vial's real numbers.
How does the mechanism of tirzepatide differ from that of semaglutide?
The primary difference lies in their receptor targets. Semaglutide is a selective GLP-1 receptor agonist, meaning it is designed to activate only the GLP-1 receptor. Tirzepatide, in contrast, is a dual agonist, engineered as a single molecule that activates both the GLP-1 receptor and the GIP (glucose-dependent insulinotropic polypeptide) receptor. Academic studies document that the addition of GIP receptor activity provides a secondary insulinotropic pathway, a feature not present in single-agonist GLP-1 peptides.
Why does the draw volume change so much when tracking a research protocol?
Protocols detailed in published studies often involve a dose titration, where the amount is systematically increased over time, for example from 2.5 mg up to 15 mg on a weekly cadence. If you reconstitute a vial to a fixed concentration, the volume needed to draw a specific dose will increase proportionally with the dose. This results in needing to calculate and draw a new, larger volume at each step of the titration schedule to obtain the correct milligram amount for that phase of the study.
What is the issue with drawing doses like 12.5 mg or 15 mg?
The challenge with higher doses is purely logistical and relates to administration volume. For a common concentration of 5 mg/mL, derived from a 10 mg vial reconstituted with 2 mL, a 12.5 mg dose requires a 2.5 mL draw, and a 15 mg dose requires a 3 mL draw. These volumes far exceed the capacity of common 1 mL insulin syringes. Therefore, researchers must plan ahead, either by using a larger syringe for administration or by reconstituting the peptide with more diluent to create a lower concentration per milliliter.

Related on Peptide Pilot

Track Tirzepatide vials automatically

Download on the App Store
Get the App